(NP (NP (NNS Requirements)) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (ADJP (NN vitamin) (JJ D-mediated)) (NN gene) (NN regulation))) (PP (IN in) (NP (JJ normal) (JJ human) (NN B) (NNS lymphocytes))))) (. .))
(S (NP-SBJ (JJ Mature) (JJ human) (NNS lymphocytes)) (VP (VBP are) (NP-PRD (NP (JJ unique) (NNS targets)) (PP (IN of) (NP (NP (CD 1) (NN alpha,25-dihydroxyvitamin) (NN D3)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3)) (-RRB- -RRB-))))) (PP (IN in) (SBAR (IN that) (S-COOD (S (NP-SBJ-16 (NP (NN vitamin) (NN D) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN VDR)) (-RRB- -RRB-))) (VP (VBP are) (RB not) (VP (ADVP (RB constitutively)) (VBN expressed) (NP (-NONE- *-16))))) (, ,) (CC and) (S (NP-SBJ-17 (JJ specific) (JJ cellular) (NN activation) (NNS signals)) (VP (VBP are) (VP (VBN required) (NP (-NONE- *-17)) (PP (IN for) (NP (DT both) (DT the) (NP-COOD (NP (NP (NN up-regulation)) (PP (IN of) (NP (NN VDR)))) (CC and) (NP (NP (NN establishment)) (PP (IN of) (NP (NP (NN reactivity)) (PP (TO to) (NP (DT the) (JJ lipophilic) (NN ligand)))))))))))))))) (. .))
(S (NP-SBJ-18 (NP (NN Treatment)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN with) (NP (NP (DT the) (NN cytokine) (NN IL-4)) (PRN (-LRB- -LRB-) (NP (NN IL-4)) (-RRB- -RRB-))))) (, ,) (PP (IN in) (DT the) (NN absence) (IN of) (NP (JJ prior) (NN activation))) (, ,) (VP-COOD (VP (VBZ induces) (NP (NP (DT a) (JJ weak) (NN up-regulation)) (PP (IN of) (NP (NN VDR) (NN expression))))) (CC but) (VP (VBZ fails) (S (NP-SBJ (-NONE- *-18)) (VP-COOD (VP (TO to) (VP (VB generate) (NP (ADJP (NP (ADJP (NN vitamin) (JJ D-responsive)) (NN element)) (-LRB- -LRB-) (NN VDRE) (-RRB- -RRB-) (JJ -reactive)) (JJ nuclear) (NN protein) (NNS complexes)))) (CC or) (VP (TO to) (VP (VB initiate) (NP (NP (DT the) (JJ genomic) (NN transcription)) (PP (IN of) (NP (NN 25-hydroxyvitamin) (NN D3) (NN 24-hydroxylase)))))))))) (. .))
(S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN by) (UCP-COOD (CC either) (NP (NP (NN ligation)) (PP (IN of) (NP (NN CD40) (NN Ag)))) (CC or) (S (NP-SBJ (-NONE- *)) (VP (VBG cross-linking) (NP (DT the) (NN Ig) (NN receptor))))))) (VP (VBZ is) (ADVP (RB also)) (ADJP-PRD (JJ insufficient) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB render) (S (NP-SBJ (NN B) (NNS lymphocytes)) (ADJP-PRD (JJ responsive) (PP (TO to) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3)))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ-20 (NP (DT this) (JJ apparent) (NN lack)) (PP (IN of) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN secosterol)))))) (VP (MD can) (VP (VB be) (VP (VBN overcome) (NP (-NONE- *-20)) (PP (IN by) (NP-LGS (NP (NN stimulation)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (DT these) (JJ cellular) (NN activation) (NNS signals)) (, ,) (SBAR (WHNP-21 (WDT which)) (S (NP-SBJ (-NONE- *T*-21)) (VP (VBP are) (ADJP-PRD (JJ sufficient) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB lead) (PP (TO to) (NP (NN G1) (NN cell) (NN cycle) (NN progression))))))))))))))))))) (. .))
(S (PP (IN In) (DT the) (NN presence) (IN of) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3))) (, ,) (NP-SBJ-23 (NP (JJ cellular) (NN activation)) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (NP (NN stimulation)) (PP (IN of) (NP (PDT such) (DT a) (NN progression))))))) (VP (VBZ appears) (S (NP-SBJ (-NONE- *-23)) (VP (TO to) (VP (VB be) (ADJP-PRD-COOD (ADJP (JJ sufficient) (PP (IN for) (NP (NP (DT the) (NN up-regulation)) (PP (IN of) (NP-COOD (NP (NN VDR) (NN message)) (CC and) (NP (NN protein))))))) (CC and) (ADJP (JJ necessary) (PP (IN for) (NP-COOD (NP (NP (DT the) (NN establishment)) (PP (IN of) (NP (NN VDRE) (NN binding) (NNS complexes)))) (CC and) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN 24-hydroxylase) (NN message)))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-24 (JJ biologic) (NNS functions)) (VP (VBP are) (VP (VP (VBN modulated) (NP (-NONE- *-24))) (, ,) (SBAR (WHPP-101 (IN in) (WHNP (IN that))) (S (NP-SBJ (DT the) (NN hormone)) (VP (VBZ inhibits) (NP (NP (NN proliferation)) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (VBN activated) (NN B) (NNS cells)))))) (PP (-NONE- *T*-101))))))) (. .))
(S (NP-SBJ (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-25 (NP (NN reactivity)) (PP (TO to) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3)))) (VP (VBZ is) (VP (ADVP (RB tightly)) (VBN regulated) (NP-26 (-NONE- *-25)) (PP (IN in) (NP (NN B) (NNS lymphocytes))) (, ,) (S (NP-SBJ (-NONE- *-26)) (VP (VBG requiring) (NP (JJ specific) (NNS signals)) (PP (IN for) (NP (PRP$ its) (NN initiation)))))))))) (. .))
